Monoamine oxidase inhibitors antagonize the acceleration of brain dopamine synthesis induced by neuroleptic drugs in vivo: implications for the treatment of Tardive dyskinesia.
D000818:Animals; D001921:Brain / Q000187:drug effects*; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000096:biosynthesis*; D006834:Hydrazines / Q000494:pharmacology; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009069:Movement Disorders / Q000188:drug therapy; D010293:Pargyline / Q000494:pharmacology; D051381:Rats; D013747:Tetrabenazine / Q000494:pharmacology; D014149:Tranquilizing Agents / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014268:Trifluoperazine / Q000494:pharmacology
D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D014149:Tranquilizing Agents; D014268:Trifluoperazine; D010293:Pargyline; D004298:Dopamine; D013747:Tetrabenazine